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Protein phosphatase 2A (PP2A) is a large family of enzymes that account for the majority of
brain Ser/Thr phosphatase activity.While PP2A enzymes collectivelymodulatemost cellular
processes, sophisticated regulatory mechanisms are ultimately responsible for ensuring
isoform-speciﬁc substrate speciﬁcity. Of particular interest to the Alzheimer’s disease (AD)
ﬁeld, alterations in PP2A regulators and PP2A catalytic activity, subunit expression, methy-
lation and/or phosphorylation, have been reported in AD-affected brain regions. “PP2A”
dysfunction has been linked to tau hyperphosphorylation, amyloidogenesis and synaptic
deﬁcits that are pathological hallmarks of this neurodegenerative disorder. Deregulation of
PP2A enzymes also affects the activity of many Ser/Thr protein kinases implicated in AD.
This review will more speciﬁcally discuss the role of the PP2A/Bα holoenzyme and PP2A
methylation in AD pathogenesis. The PP2A/Bα isoform binds to tau and is the primary tau
phosphatase. Its deregulation correlates with increased tau phosphorylation in vivo and in
AD. Disruption of PP2A/Bα-tau protein interactions likely contribute to tau deregulation in
AD. Signiﬁcantly, alterations in one-carbon metabolism that impair PP2A methylation are
associated with increased risk for sporadic AD, and enhanced AD-like pathology in animal
models. Experimental studies have linked deregulation of PP2A methylation with down-
regulation of PP2A/Bα, enhanced phosphorylation of tau and amyloid precursor protein, tau
mislocalization, microtubule destabilization and neuritic defects. While it remains unclear
what are the primary events that underlie “PP2A” dysfunction in AD, deregulation of PP2A
enzymes deﬁnitely affects key players in the pathogenic process. As such, there is growing
interest in developing PP2A-centric therapies for AD, but this may be a daunting task
without a better understanding of the regulation and function of speciﬁc PP2A enzymes.
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THE PUZZLING DIVERSITY OF THE “PP2A” FAMILY
Protein phosphatase 2A (PP2A) refers to a ubiquitous, highly con-
served family of at least 96 serine/threonine phosphatases that
represent 0.1-1% of total cellular proteins and play a crucial
role in regulating most cellular functions (Reviewed in Virshup
and Shenolikar, 2009). The typical and primary mammalian
holoenzyme is a heterotrimeric complex between the catalytic C
subunit (PPP2CA or PPP2CB isoforms), a scaffolding A subunit
(PPP2R1A or PPP2R1B isoforms) and a regulatory B subunit,
which belongs to one of four distinct families: B (PPP2R2), B’
(PPP2R5), B” (PPP2R3), or B”’/striatins (PPP2R4). B subunits
are encoded by 15 different genes, and 23 isoforms have been
identiﬁed so far. A comparativelymuch smaller amount of endoge-
nous dimeric [AC] core enzymes, and PP2A complexes containing
the catalytic C subunit coupled to the alpha four subunit or
other PP2A-speciﬁc modulators, have also been isolated in vivo
(Reviewed in Sents et al., 2013).
Although “PP2A” represents a major portion of Ser/Thr phos-
phatase activity inmost tissues, genetic studies have pointed to the
important observation that each PP2A isoform likely exerts non-
redundant cellular functions (Zhao et al., 1997). Consequently,
scientists should ideally refrain from using ambiguous and impre-
cise statements, such as “PP2A regulates this” or “activation of
PP2A does that,” as those do not take into account the exquisite
diversity and functional selectivity of PP2A enzymes. Indeed,
despite the tremendous functional signiﬁcance of the “PP2A”
family, isoform-speciﬁc substrates remain in large part to be char-
acterized in vivo, including in the central nervous system (CNS).
The unfortunate lack of valid isoform-speciﬁc PP2A antibodies,
inhibitors/activators and activity assays, the complexity of PP2A
regulation, and the fact that most “PP2A” enzymes play essential
cellular functions have all historically combined to hinder progress
in dissecting the role of each speciﬁc member of the “PP2A”
family.
THE MIND-BLOWING SOPHISTICATION OF “PP2A”
REGULATION
Protein phosphatase 2A regulation is highly complex, involving
not only the interplay of speciﬁc regulatory subunits and modula-
tors, but also post-translational modiﬁcations, protein–protein
interactions and subcellular compartmentalization (Figure 1).
Notably, these interwoven regulatory processes coalesce to ensure
PP2A isoform-speciﬁc functional speciﬁcity, as described below:
PP2A POST-TRANSLATIONAL MODIFICATIONS
Protein phosphatase 2A catalytic subunit is uniquely methylated
on Leu-309 by the dedicated leucine carboxyl methyltransferase-
1 (LCMT-1; Lee et al., 1996; De Baere et al., 1999). Like all
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FIGURE 1 | Schematic overview of the intricate regulation of PP2A
enzymes. Major PP2A holoenzymes of this very large family (>96 enzymes)
are heterotrimers containing a scaffolding “A” (one of two isoforms), a
catalytic “C” (one of two isoforms), and one variable regulatory “B” subunit
(one of twenty three isoforms). PP2A subunits are subjected to
post-translational modiﬁcations, including methylation of the catalytic subunit
on a conserved Leucine-309 residue, and phosphorylation. Endogenous
subunit interactions, interaction of PP2A subunits with a variety of viral and
cellular proteins, and binding of speciﬁc PP2A inhibitors and modulatory
proteins to the catalytic subunit, all combine to modulate PP2A catalytic
activity and ensure PP2A isoform-speciﬁc targeting and substrate speciﬁcity.
Speciﬁc modulatory proteins also critically regulate PP2A biogenesis and
stability. In addition, many compounds are known to enhance PP2A catalytic
activity. See text for details.
methyltransferases, LCMT1 activity depends on the supply of
the universal methyl donor, S-adenosylmethionine (SAM), and is
inhibited by S-adenosylhomocysteine (SAH; Leulliot et al., 2004;
Sontag et al., 2007). Conversely, the PP2A-speciﬁc methylesterase
PME-1 can directly bind to the active site of the catalytic subunit,
remove the methyl group and inactivate PP2A by evicting man-
ganese ions required for phosphatase activity (Xing et al., 2008).
Protein complexes containing PME-1 coupled to demethylated,
inactivePP2Ahavebeen isolated in vivo (Ogris et al., 1999).Methy-
lation is thought to play a critical role in the biogenesis of PP2A
holoenzymes. Many groups have reported that altering the overall
methylation status of PP2A catalytic subunit can lead to changes
in cellular PP2A subunit composition, and in turn, substrate
speciﬁcity (Reviewed in Janssens et al., 2008). Signiﬁcantly, down-
regulation of LCMT1 expression leads to a signiﬁcant decrease of
PP2A methylation and concomitant loss of PP2A holoenzymes
containing the regulatory Bα (or PPP2R2A) subunit (PP2A/Bα;
Lee and Pallas, 2007; Sontag et al., 2008; MacKay et al., 2013).
PP2A enzymes can also become transiently inactivated following
tyrosine phosphorylation of the catalytic subunit at the putative
Tyr-307 site, via activation of src kinase, epidermal growth factor
receptor or insulin signaling (Chen et al., 1992). Other modiﬁ-
cations of PP2A C subunit include ubiquitination, which targets
PP2A for degradation (McConnell et al., 2010), and tyrosine nitra-
tion that increases PP2A activity in endothelial cells (Wu andWil-
son, 2009). Adding another layer of complexity to the regulation
of PP2Aholoenzymes, protein kinaseA-mediated serine phospho-
rylation of selective PPP2R5A and PPP2R5D regulatory subunits
belonging to the B’ family can also modulate PP2A catalytic activ-
ity (Ahn et al., 2007; Kirchhefer et al., 2014). A recent report also
indicates the existence of regulated phosphorylation of the scaf-
folding A subunit on Ser/Thr residues, which affects its binding to
the catalytic subunit and PP2A signaling in the heart (Kotlo et al.,
2014). Sequence analyzes predict additional post-translational
modiﬁcations in PP2A subunits that remain to be validated and
characterized.
DIRECT CONTROL OF PP2A CATALYTIC ACTIVITY
Natural toxins such as okadaic acid, calyculin, and fostriecin
(Reviewed in Swingle et al., 2007), and endogenous nuclear
inhibitors called I1PP2A and I2PP2A/SET (Li and Damuni, 1998),
can directly bind to the catalytic subunit and inhibit the phos-
phatase activity of the entire family of PP2A enzymes. Conversely,
many endogenous small molecules, comprising metal cations,
ceramides and polyamines, can enhance the activity of PP2A
enzymes (Reviewed in Voronkov et al., 2011).
REGULATORY PP2A SUBUNITS AND PP2A MODULATORS
Subunit interactions within the PP2A enzymatic complex can
directly modulate PP2A catalytic activity (Kamibayashi et al.,
1991). Regulatory B subunits play a distinctively important
role in controlling PP2A substrate speciﬁcity. For instance, the
Bα subunit speciﬁcally and markedly facilitates dephosphory-
lation of tau by PP2A (Sontag et al., 1996; Xu et al., 2008).
Furthermore, direct interaction of PP2A catalytic subunit with
speciﬁc regulatory proteins, including PME-1, LCMT1, the alpha4
subunit, and the PP2A phosphatase activator PTPA, critically
modulates PP2A biogenesis and stability. Together, those also
participate in the complex surveillance mechanisms that prevent
untimely, detrimental PP2A activation within cells (Reviewed in
Sents et al., 2013).
PROTEIN–PROTEIN INTERACTIONS
Through one ormore of their composing subunits, PP2A enzymes
interact with a wide variety of cellular proteins (For example see
Sontag, 2001), including protein kinases, receptors, cytoskele-
tal proteins and transcription factors, as well as viral proteins
(Reviewed in Guergnon et al., 2011). Of particular relevance to
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the Alzheimer’s disease (AD) ﬁeld, PP2A/Bα holoenzymes can
directly bind to the microtubule-associated protein tau (Sontag
et al., 1999, 2012; Xu et al., 2008). PP2A enzymes can also associate
with protein kinases that have been linked to AD, such as glycogen
synthase kinase 3β (GSK3β) and cyclin-dependent kinase 5 (cdk5;
Plattner et al., 2006), and neuronal receptors, e.g., the NMDA
receptor (Chan and Sucher, 2001) and themetabotropic glutamate
receptor 5 (Mao et al., 2005; Arif et al., 2014).
SUBCELLULAR COMPARTMENTALIZATION
Protein phosphatase 2A regulatory subunits are expressed in a
cell- and tissue-speciﬁc manner, which is responsible for the
isoform-speciﬁc distribution of PP2A in the brain (Strack et al.,
1998). They can also inﬂuence the subcellular localization of
PP2A either directly or indirectly by binding to speciﬁc intra-
cellular proteins. For instance, some B’ subunits target PP2A
to the nucleus (McCright et al., 1996) or the centrosome (Flegg
et al., 2010); Bα subunits can direct some PP2A pools to micro-
tubules, which could serve as a cytoskeletal reservoir of inac-
tive enzymes (Sontag et al., 1995; Hiraga and Tamura, 2000).
PP2A regulatory proteins can further affect the phosphatase
distribution. For example, PME-1 stabilizes a nuclear pool of
inactive PP2A enzymes (Longin et al., 2008), while methylation
by LCMT1 inﬂuences the amounts of PP2A enzymes bound
to plasma membrane microdomains (Sontag et al., 2013). Yet,
much remains to be learned about the precise mechanisms
that control PP2A translocation to discrete subcellular compart-
ments. In any case, the regulated formation of speciﬁc PP2A
isoform-containing multi-protein scaffolds likely contributes to
the general spatiotemporal control of many signaling pathways in
the CNS.
THE MULTIFACETED DEREGULATION OF “PP2A” IN AD
Over the past years, several alterations in PP2A and PP2A regu-
latory enzymes have been identiﬁed in AD autopsy brain tissue
(Figure 2A), and are described as follows:
ALTERATIONS IN PP2A
There is a signiﬁcant decrease in total PP2A activity measured
in AD cortical and hippocampal brain homogenates (Gong
FIGURE 2 | Overview of PP2A dysfunction in AD and its link with the
deregulation of tau. (A) Altered PP2A subunit expression, activity and
post-translational modiﬁcations have been described in AD autopsy brain
tissue. Some of these changes may be mediated by alterations in speciﬁc
PP2A modulatory proteins (LCMT1, PTPA, alpha4) and endogenous PP2A
inhibitors (I1PP2A and I2PP2A) that have also been reported in AD autopsy
brain tissue. They also decrease the interaction of PP2A with tau. (B) The
biogenesis of the PP2A/Bα holoenzyme, the primary Ser/Thr tau
phosphatase in vivo, is believed to be controlled by Leu-309 methylation
of PP2A catalytic subunit by LCMT1. This reaction requires the supply of
SAM, the universal methyl donor, and is inhibited by SAH. The PP2A
methylesterase, PME-1, can demethylate and inactivate PP2A through
distinct mechanisms, and form a complex with inactive PP2A enzymes.
Those inactive complexes could be-reactivated via the action of the PP2A
activator PTPA, allowing for subsequent methylation of PP2A C subunit.
Many brain Ser/Thr protein kinases, including GSK3β, oppose the action
of PP2A/Bα and promote tau phosphorylation. Inhibition and/or
down-regulation of PP2A can enhance tau phosphorylation directly by
preventing its dephosphorylation, or indirectly by up-regulating tau
kinases.
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et al., 1993; Gong et al., 1995; Sontag et al., 2004b). Deﬁcits in
PP2A activity are in line with the reported down-regulation
of PP2A catalytic C subunit at the gene (Loring et al., 2001),
mRNA (Vogelsberg-Ragaglia et al., 2001) and protein (Sontag
et al., 2004b) expression levels in AD. In contrast, “PP2A” expres-
sion levels are increased in AD astrocytes (Pei et al., 1997). More
speciﬁcally, decreased expression levels of PP2A regulatory Bγ
(or PPP2R2C) and B’ε (or PPP2R5E) subunit mRNAs in the
hippocampus (Vogelsberg-Ragaglia et al., 2001), and cortical Bα
subunit (Sontag et al., 2004b) have been reported in AD. Notably,
the loss of neuronal PP2A/Bα holoenzymes correlates with the
down-regulation of PP2A methylation and severity of phospho-
rylated tau (P-tau) pathology inAD-affected brain regions (Sontag
et al., 2004a,b). Lastly, increased phosphorylation of PP2A at Tyr-
307 has been found in P-tau-rich, tangle-bearing neurons from
post-mortem brain (Liu et al., 2008b).
ALTERATIONS IN PP2A REGULATORY PROTEINS
Signiﬁcantly, down-regulation of LCMT1 protein expression par-
allels the deﬁcits in PP2A methylation observed in AD (Sontag
et al., 2004a). Up-regulation of I1PP2A and I2PP2A, and mislocal-
ization and cleavage of I2PP2A, could underlie the inactivation
of PP2A in AD neocortical neurons (Tanimukai et al., 2005).
Decreased expression levels of PTPA in AD brain tissue may
also lead to inactivation of PP2A by indirectly increasing levels
of PP2A phosphorylated at the Tyr-307 site (Luo et al., 2013).
Lastly, increased calpain-mediated cleavage of alpha4, which criti-
cally modulates PP2A stability, could be responsible for increased
degradation of PP2A catalytic subunit inAD (Watkins et al., 2012).
Collectively, those studies point to a central role for PP2A dys-
function inADpathogenesis. However, the primarymechanism(s)
responsible for such multilayered and confounding deregulation
of PP2A enzymes and modulators remain obscure.
IN VIVO IMPAIRMENT OF “PP2A” LEADS TO AD-LIKE
PATHOLOGY AND COGNITIVE DEFECTS
In vivo use of phosphatase inhibitors such as okadaic acid has
been shown in many studies to induce cognitive impairment and
widespread neurotoxic effects that are reminiscent of the hall-
mark pathological processes occurring in AD pathology, i.e., the
accumulation of P-tau, amyloidogenesis, synapse loss and neu-
rodegeneration (Malchiodi-Albedi et al., 1997; Arendt et al., 1998;
Sun et al., 2003; Kamat et al., 2013). However, these inhibitors lack
speciﬁcity towardPP2Aat the concentrations used in vivo (Swingle
et al., 2007). Their usefulness is also dramatically limited by their
inherent lack of selectivity toward speciﬁc PP2A isoforms. Not
surprisingly, inhibition of total cellular PP2A activity ultimately
leads to neuronal cell death.
More speciﬁc and targeted manipulation of PP2A through
experimental overexpression and knock-down of particular sub-
units and/or modulatory proteins, has more convincingly demon-
strated the implication of PP2A in AD. Knock-down of PP2A
catalytic subunit (Kins et al., 2001) or PP2A B’δ (or PPP2R5D)
regulatory subunit (Louis et al., 2011), and expression of the
methylation-site L309A C subunit mutant (Schild et al., 2006) all
induce AD-like tau phosphorylation in transgenic mice. Genetic
studies in Drosophila also conﬁrm the critical role played by
PP2A in modulating P-tau toxicity (Steinhilb et al., 2007). More-
over, expression of an I2PP2A fragment can recapitulate AD-like
pathology in rat brain (Wang et al., 2010). However, simi-
larly to exogenous inhibitors, I2PP2A indiscriminately inhibits all
PP2A isoforms, including enzymes that may be irrelevant to the
neurodegenerative process in AD.
THE INTIMATE INTERRELATIONSHIP BETWEEN
DEREGULATION OF “PP2A” AND AD BRAIN PROTEIN
KINASES
It is well recognized now that the imbalance between protein
kinases and phosphatases is a major contributor to the neurode-
generative process in AD. At pretty much each crossroad of major
signal transduction pathways, there are dedicated PP2A enzymes
ready to ambush and dephosphorylate selective Ser/Thr kinase(s).
Yet again, for each protein kinase/protein phosphatase couple,
the precise nature of the PP2A isoform involved is not always
known. Speciﬁc PP2A inhibition has been proven to lead to in
vivo deregulation of many major brain Ser/Thr kinases implicated
in AD, including GSK3β (Wang et al., 2010; Louis et al., 2011),
cdk5 (Louis et al., 2011; Kimura et al., 2013), extracellular signal-
regulated kinase (ERK) and JNK (Kins et al., 2003). In fact, PP2A
inhibition can override the inhibition of these key AD-tau kinases
(Planel et al., 2001). Apart from affecting tau phosphorylation,
abnormal activation of GSK3β, cdk5, and ERK has been linked to
cytoskeletal abnormalities (microtubules, neuroﬁlaments), alter-
ations in amyloid precursor protein (APP) phosphorylation and
processing, impairment of neurogenesis, alterations in synap-
tic plasticity and induction of apoptotic processes (Reviewed
in Crews and Masliah, 2010; Medina and Avila, 2013, 2014).
Thus, by deregulating the activity of central AD protein kinases,
PP2A dysfunction can promote aberrant stimulation of signal-
ing cascades that contribute to neuronal and synaptic damage
in AD.
Conversely, some Ser/Thr protein kinases can in turn mod-
ulate PP2A. For instance, activated GSK3β has been reported
to induce PP2A inactivation via several mechanisms: phospho-
rylation of PP2A on Tyr307 (Yao et al., 2011); demethylation of
PP2A on Leu309 through inhibition of LCMT1 and up-regulation
of PME1 (Yao et al., 2012); and accumulation of I2PP2A (Liu
et al., 2008a). Besides Ser/Thr kinases, the protein tyrosine kinase
src promotes the phosphorylation of PP2A on Tyr-307, result-
ing in PP2A inactivation and subsequent tau phosphorylation
(Xiong et al., 2013; Arif et al., 2014). Nonetheless, the intercon-
nection between the deregulation of these various protein kinase/
PP2A-dependent signaling cascades and AD pathogenesis is still
unclear.
DEREGULATION OF PP2A/Bα: A MAJOR CONTRIBUTOR TO
PHOSPHO-TAU PATHOLOGY
Notably, “PP2A”mediates ∼71% of total tau phosphatase activity
in the human brain (Liu et al., 2005). While many PP2A holoen-
zymes have the potential to indirectly affect tau phosphorylation
bymodulating key tauprotein kinases (For example see Louis et al.,
2011), biochemical and structural studies have demonstrated that
PP2A/Bα is the primary PP2A isoform that mediates tau dephos-
phorylation (Sontag et al., 1996, 1999; Xu et al., 2008). Speciﬁc
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inhibition of PP2A/Bα is associated with enhanced tau phos-
phorylation at many AD-like phosphoepitopes, and subsequent
inability of tau to bind to and stabilize microtubules (Sontag et al.,
1996). Deregulation of PP2A/Bα alone also affects microtubule
stability (Nunbhakdi-Craig et al., 2007) and neurite outgrowth
(Sontag et al., 2010) in neuroblastoma cells. Since PP2A/Bα is a
major brain enzyme, its loss has also the potential to deregu-
late many neuronal signaling pathways. As described earlier, it
is especially signiﬁcant that the biogenesis of PP2A/Bα holoen-
zymes is intimately related to the methylation state of PP2A.
Accordingly, the phosphorylation state of tau is vulnerable to
neuronal changes in PP2A methylation/demethylation processes
(Figure 2B).
It is noteworthy that PP2A/Bα can directly bind to tau via a
domain encompassing the microtubule-binding of tau; this inter-
actionmaximizes the efﬁciency of tau dephosphorylation by PP2A
(Sontag et al., 1999; Xu et al., 2008; Figure 3A). PP2A/Bα has
more afﬁnity for adult four-repeat tau than three-repeat tau iso-
forms (Sontag et al., 1999). Inactive pools of PP2A/Bα are also
directly associated with microtubules, so that binding to tau and
dephosphorylation of tau could in principle only occur when
FIGURE 3 | Deregulation of PP2A-tau protein–protein interactions in
AD. (A)The PP2A/Bα holoenzyme can directly interact with three- or
four-repeat human tau isoforms via a domain encompassing the
microtubule-binding repeats (orange), resulting in tau dephosphorylation. A
speciﬁc proline-rich motif (yellow) that contains theThr231 phosphorylation
site plays a critical role in modulating PP2A-tau protein–protein interactions.
(B) PP2A-tau protein–protein interaction can be inhibited in vitro by: (1)
Alterations in tau, including AD-like phosphorylation and FTDP-17 missense
mutations; (2) decreased expression levels of PP2A methylation and
PP2A/Bα in AD; (3) Fyn kinase and pseudophosphorylated RpTPPKSP
peptides. Disruption of normal PP2A-tau interactions is predicted to affect
tau phosphorylation state and function.
both tau and PP2A fall off the microtubule cytoskeleton (Son-
tag et al., 1999; Hiraga and Tamura, 2000). Notably, tau missense
mutations found in frontotemporal dementia with Parkinson-
ism linked to chromosome 17 (FTDP-17; Goedert et al., 2000)
and AD-mimicking tau phosphorylation in proline-rich motifs
(Eidenmuller et al., 2001) inhibit the association of tau with
PP2A (Figure 3B). Recently, we identiﬁed a speciﬁc RTPPKSP
Proline-rich motif in tau that critically modulates PP2A-tau
protein–protein interactions (Sontag et al., 2012). Phosphoryla-
tion of the Thr-231 residue in this motif markedly decreases the
afﬁnity of tau for PP2A. This is potentially physiologically sig-
niﬁcant since phosphorylation of tau at Thr-231, a target site
for ERK2, GSK3β, and cdk5, occurs early in AD and can fur-
ther inhibit the ability of PP2A/Bα to dephosphorylate other
major AD-tau phosphoepitopes (Landrieu et al., 2011). Moreover,
the RTPPKSP motif is also a binding site for SH3 domain-
containing proteins including Fyn, a protein tyrosine kinase that
phosphorylates tau on Tyr residues and plays a major role in
AD pathogenesis (Lee, 2005). Indeed, Fyn kinase and PP2A
compete for tau binding in vitro (Sontag et al., 2012). Con-
versely, decreased PP2A methylation and PP2A/Bα levels in
AD will disrupt normal PP2A-tau interactions (Sontag et al.,
2007), thereby preventing PP2A-mediated tau dephosphoryla-
tion while allowing for enhanced binding of Fyn kinase or other
regulators to the tau proteins. In theory, this could lead to
a net increase in tau phosphorylated at both Ser/Thr and Tyr
sites, as observed in AD; in turn, abnormally elevated levels
of phosphorylation will disrupt tau localization and function
(Reviewed in Martin et al., 2011). These in vitro studies under-
score the critical importance of tau as a scaffold for key signaling
molecules implicated in AD. Indeed, the signiﬁcance of disrupt-
ing these tau protein–protein interactions for deregulation of tau
and neuronal homeostasis has been largely underestimated to
date.
THE EMERGING SIGNIFICANCE OF ALTERED PP2A
METHYLATION IN AD
The deregulation of PP2A methylation in AD is especially inter-
esting, not only because it can lead to a loss of PP2A/Bα, a
major tau regulator, but also because PP2A methylation state
is intimately linked to the integrity of one-carbon metabolism,
which regulates SAM supply (Reviewed in Fowler, 2005). It is
well documented that hyperhomocysteinemia, and low folate/
B12-vitamin status that independently lead to elevations of homo-
cysteine levels, can induce disturbances in the brain methylation
potential. Such alterations are associated with increased risk
for sporadic AD and cognitive decline in humans (Reviewed in
Selhub et al., 2010; Zhuo et al., 2011; Bottiglieri, 2013). Remark-
ably, impairment of one-carbon metabolism in animal models
can reproduce AD-like pathological features: accumulation of
P-tau (Sontag et al., 2007; Zhang et al., 2008; Wei et al., 2011);
enhanced amyloidogenesis (Pacheco-Quinto et al., 2006; Zhang
et al., 2009; Zhuo et al., 2010; Zhuo and Pratico, 2010); increased
phosphorylation of APP at the regulatory Thr-668 site (Son-
tag et al., 2007; Zhang et al., 2009); increased sensitivity to
amyloid toxicity (Kruman et al., 2002); and cognitive impair-
ment (Bernardo et al., 2007; Wei et al., 2011; Rhodehouse et al.,
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FIGURE 4 | Model for the link between alterations in one-carbon
metabolism, deregulation of PP2A methylation and AD-like pathology.
Dietary B-vitamin deﬁciency, genetic polymorphisms in key enzymes that
metabolize folate and homocysteine, drugs (e.g., the anti-folate drug,
methotrexate), diseases (e.g., liver disease) and aging can all lead to
impairment of one-carbon metabolism. In turn, alterations in the
methylation cycle result in decreased LCMT1 activity and/or expression
levels, and subsequent down-regulation of PP2A methylation and PP2A/Bα
holoenzymes. This is associated with the accumulation of phosphorylated
tau and APP proteins in vivo. Experiments in cultured cells and in vitro also
link alterations in neuronal PP2A methylation with disruption of PP2A-tau
protein–protein interactions, alterations in the subcellular targeting of PP2A
and tau, APP processing, microtubule stability, and neuritic defects.
2013). Many of these effects appear now to be mediated in
part by deregulation of PP2A (Figure 4). Dietary folate and
B-vitamin deﬁciency (Sontag et al., 2008; Nicolia et al., 2010)
and elevated homocysteine levels (Sontag et al., 2007, 2013;
Zhang et al., 2008) lead to down-regulation of PP2A methyla-
tion and concomitant phosphorylation of tau and/or APP in
vivo. In cultured cells, deregulation of PP2A methylation also
affects APP processing (Sontag et al., 2007), neurite outgrowth
(Sontag et al., 2010) and tau distribution (Sontag et al., 2013).
It is worth mentioning that besides PP2A, other pathways can
contribute to the link between impaired one-carbon metabolism
and AD-like neurodegeneration. For instance, altered methyla-
tion of genes responsible for production of amyloid-β peptides
is associated with enhanced amyloidogenesis (Fuso and Scarpa,
2011). In this context, it is especially interesting that age-
related epigenetic changes in genes that participate in methylation
homeostasis have been identiﬁed in late-onset AD (Wang et al.,
2008).
CONCLUDING REMARKS AND PERSPECTIVES: THE TAXING
CHALLENGE OF DEVELOPING PP2A-CENTRIC THERAPEUTIC
APPROACHES FOR AD
Altogether, there is overwhelming evidence from experimental
studies that “PP2A” dysfunction is a key player in the devel-
opment of P-tau pathology in AD. Few experimental studies
also point to a link between “PP2A” deregulation and amy-
loidogenesis, but underlying mechanisms remain sketchy. PP2A
enzymes also oppose the activity of many brain protein kinases
up-regulated in AD. Consequently, there is growing interest in
developing PP2A-targeted therapies for AD, especially to coun-
teract P-tau pathology. Many compounds are already known to
modulate PP2A activity by several direct and indirect mecha-
nisms (Voronkov et al., 2011). In vivo studies have shown that
some experimental compounds and drugs currently used clini-
cally can “activate PP2A” and subsequently reverse AD-like tau
phosphorylation, for instance: sodium selenate, by increasing
“PP2A activity” through unknown mechanisms (van Eersel et al.,
2010); the anti-AD drug,memantine, by targeting I2PP2A (Chohan
et al., 2006); and the anti-diabetic drug, metformin, by interfering
with PP2A degradation (Kickstein et al., 2010). Thus, can simply
“PP2A activators” be the next cure for AD and other tauopathies
(Voronkov et al., 2011)?
We argue that there are still many hurdles to overcome to
develop valid PP2A-based therapies. First, it is clear that the
deregulation of PP2A and PP2A regulatory proteins in AD is
multidimensional and intrinsically complex (Figure 2A), beg-
ging the question as to what is the primary mechanism of PP2A
dysfunction that should be preferentially targeted in clinical tri-
als? It is unlikely that a single compound will overcome all the
many-sided PP2A deﬁcits that are present in AD. It is not clear
either how exactly pharmacological “PP2A (re)activation” will
restore the collective function of speciﬁc PP2A holoenzymes and
PP2A modulators that become down-regulated at the protein
level in AD neurons. Next, as reported for clinical AD kinase
inhibitors, speciﬁcity and side-effects are likely to be a huge
issue, due to the broad spectrum of PP2A enzymes, their pro-
fuse abundance and their essential role. While PP2A/Bα is the
primary tau phosphatase, none of the compounds tested so far
have demonstrated isoform speciﬁcity, so that they are likely to
interfere with the regulation of a plethora of PP2A enzymes that
are irrelevant to the overall neurodegenerative process. Drugs
may also target PP2A enzymes outside the brain and in brain
regions not primarily involved in the disease process. The reg-
ulation of PP2A is still not well understood, and effects of
indiscriminate and long-term “PP2A” activation or interference
with vital PP2A-regulatory mechanisms are not known. Further-
more, pathological brain changes manifest at least one decade
before appearance of AD symptoms (Sperling et al., 2011). Thus,
one needs to take into account that treatment with pharmaceutical
PP2A drugs may require to be started early and prolonged for a
long period of time, which increases chances for compensatory
mechanisms and side-effects. Lastly, the observation that PP2A-
targeting compounds can improveAD-like pathology derives from
testing in mouse models that do not reproduce the complex-
ity of the pathology encountered in their human counterparts.
For instance, the mice utilized do not exhibit the multifaceted
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aspects of PP2A deregulation that are inherent to AD autopsy
tissue.More signiﬁcantly, they donot exhibit themetabolic deﬁcits
observed in AD patients. For instance, epidemiological studies
show that AD patients have low plasma folate status (Lopes da
Silva et al., 2013), which can negatively impact PP2A methyla-
tion (Sontag et al., 2008). Therapeutic approaches may also need
to take into account the existence of common human polymor-
phisms (Naj et al., 2010; Hua et al., 2011; Coppede et al., 2012;
Mansouri et al., 2013) and age-related epigenetic changes (Wang
et al., 2008) in folate-related genes that affect folate status and
have been associated with late-onset AD. The resulting impair-
ment of methylation pathways may offset the efﬁcacy of potential
PP2A agonists. In this context, it is worth mentioning that dietary
compounds that target one-carbon metabolism and therefore
inﬂuence PP2A methylation, such as betaine (Chai et al., 2013),
SAM (Fuso et al., 2012), and B-vitamin supplementation (Zhang
et al., 2008;Wei et al., 2011), all improve AD-like pathological fea-
tures in vivo. While promising, the validity of these therapeutic
approaches for AD needs to be further investigated in clinical tri-
als (Morris, 2012; Bottiglieri, 2013). In conclusion, it is paramount
to gain a better understanding of the regulation and function
of speciﬁc PP2A isoforms in normal neuronal homeostasis to
guarantee success of novel PP2A-centric therapeutic strategies
for AD.
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